Significance of pretransplant and de novo anti-HLA antibody detection after simultaneous pancreas-kidney transplantation

Introduction. Nowadays, there are few studies concerning assessment of the clinical significance of determining the level of pretransplant and de novo anti-HLA antibodies in patients after simultaneous pancreas-kidney transplantation.
Aim. The study of the incidence, timing of formation and specificity of pretransplant and de novo anti-HLA antibodies in patients after simultaneous pancreas-kidney transplantation.
Material and methods. We conducted a prospective and retrospective research to study the incidence, timing of formation and specificity of pretransplant and de novo anti-HLA antibodies in 55 patients after simultaneous pancreas-kidney transplantation performed at the N.V. Sklifosovsky Research Institute for Emergency Medicine from 2008 to 2022.
Results. There were 4 patients with preformed anti-HLA antibodies (7%). The formation of de novo anti-HLA antibodies after simultaneous pancreas-kidney transplantation was observed in 17 patients (31%). There were 5 patients with antiHLA class I, 3 patients with anti-HLA class II, 3 patients with anti-HLA class I and II, 5 patients with anti-MICA and 1 patient with both classes of anti-HLA and anti-MICA. The formation of de novo anti-HLA antibodies significantly increased the incidence of acute rejection (47% compared with 13%, p=0.014).
Conclusion. The frequency of pretransplant and de novo anti-HLA antibody detection in the recipients at our Center is comparable to published data from other transplant centers. We obtained evidence that the formation of de novo antiHLA antibodies increases the incidence of acute rejection after simultaneous pancreas-kidney transplantation.

1. Parajuli S, Alagusundaramoorthy S, Aziz F, Garg N, Redfield RR, Sollinger H, et al. Outcomes of pancreas transplant recipients with de novo donor-specific antibodies. Transplantation. 2019;103(2):435–440. PMID: 29994978 https://doi.org/10.1097/TP.0000000000002339

2. Malheiro J, Martins LS, Tafulo S, Dias L, Fonseca I, Beirão I, et al. Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney transplantation. Transpl Int. 2016;29(2):173–183. PMID: 26404891 https://doi.org/10.1111/tri.12687

3. Cantarovich D, De Amicis S, Akl A, Devys A, Vistoli F, Karam G, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant. 2011;11(12):2737–2746. PMID: 21906255 https://doi.org/10.1111/j.1600-6143.2011.03729.x

4. Aziz F, Mandelbrot D, Parajuli S, Al-Qaoud T, Redfield R, Kaufman D, et al. Alloimmunity in pancreas transplantation. Curr Opin Organ Transplant. 2020;25(4):322–328. PMID: 32692039 https://doi.org/10.1097/MOT.0000000000000776

5. Mittal S, Page SL, Friend PJ, Sharples EJ, Fuggle SV. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant. 2014;14(7):1664–1671. PMID: 24866735 https://doi.org/10.1111/ajt.12750

6. Ladowski JM, Mullins H, Romine M, Kloda D, Young C, Hauptfeld-Dolejsek V, et al. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation. Hum Immunol. 2021;82(3):139–146. PMID: 33390268 https://doi.org/10.1016/j.humimm.2020.12.009

7. Khan SM, Sumbal R, Schenk AD. Impact of anti-HLA de novo donor specific antibody on graft outcomes in pancreas transplantation: a meta-analysis. Transplant Proc. 2021;53(10):3022–3029. PMID: 34772490 https://doi.org/10.1016/j.transproceed.2021.08.052

8. Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, et al. Complement-activating donorspecific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis. PLoS Med. 2018;15(5):e1002572. https://doi.org/10.1371/journal.pmed.1002572 Erratum in: PLoS Med. 2018;15(7):e1002637. PMID: 29799874.

9. Perosa M, Vidigal AC, Danziere F, De Marco R, Malheiros D, Branez J, et al. 306.5: a prospective study of donorspecific anti-HLA antibody monitoring in pancreas transplantation. Transplantation. 2021;105(12Suppl 1):S20. PMID: 34908324 https://doi.org/10.1097/01.tp.0000804388.98141.6e

10. Chaigne B, Geneugelijk K, Bédat B, Ahmed MA, Hönger G, De Seigneux S, et al. Immunogenicity of anti-HLA antibodies in pancreas and islet transplantation. Cell Transplant. 2016;25(11):2041–2050. PMID: 27196533 https://doi.org/10.3727/096368916X691673

11. Mujtaba MA, Fridell JA, Higgins N, Sharfuddin AA, Yaqub MS, Kandula P, et al. Early findings of prospective antiHLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience. Clin Transplant. 2012;26(5):E492–499. PMID: 22938159 https://doi.org/10.1111/ctr.12005

12. Baranwal AK, Mehra NK. Major histocompatibility complex class I chainrelated A (MICA) molecules: relevance in solid organ transplantation. Front Immunol. 2017;8:182. PMID: 28293239 https://doi.org/10.3389/fimmu.2017.00182

13. Zaitseva GA, Kiseleva AN, Paramonov IV. Major histocompatibility complex class I chain-related gene A (MICA) and B (MICB) polymorphism. Russian journal of hematology and transfusiology. 2016;61(2):100–104. (In Russ.). https://doi.org/10.18821/0234-5730-2016-61-2-100-104